FDA approved MEK inhibitors.

Sr. no.	FDA drugs	FDA approved	Target	Side effects	References
01	Trametinib	In 2013	MEK1/2	Fatigue rash, diarrhea, peripheral edema, and acneiform dermatitis	62
02	Selumetinib	In 2020	MEK1	Acneiform rash, gastro-intestinal effects, and asymptomatic creatine kinase elevation	63
03	Cobimetinib	In 2015	MEK1/2	Gastrointestinal disorders rash, pyrexia, increased blood CPK,12 and chorioretinopathy	64
04	Binimetinib	In 2018	MEK1/2	Rash, nausea, diarrhoea, peripheral oedema, and fatigue	65